Tuesday, July 7, 2015

Stryker says it will buy MAKO Surgical for $1.6 billion

Consolidation in the medical device segment of health care continued Wednesday as Stryker Corp., said it will pay $1.65 billion to buy MAKO Surgical Corp..

Stryker says it will buy MAKO Surgical for $1.6 billion

0 comments
Travel Deals

Consolidation in the medical device segment of health care continued Wednesday as Stryker Corp., said it will pay $1.65 billion to buy MAKO Surgical Corp.

Stryker is based in Kalamazoo, Mich., but sells nationally and competes with Johnson & Johnson's Synthes/DePuy division among others. Synthes was based in West Chester until it was bought by J&J for $19.7 billion.

MAKO was founded only in 2004 and is based in Fort Lauderdale, Fla. Most of its acclaim within the industry was around its robotic devices used by surgeons.

"MAKO has established a compelling technology platform in robotic assisted surgery which we believe has considerable long term potential in joint reconstruction," Stryker Chief Executive Officer Kevin A. Lobo said in a statement. "The acquisition of MAKO combined with Stryker's strong history in joint reconstruction, capital equipment (operating room integration and surgical navigation) and surgical instruments will help further advance the growth of robotic assisted surgery. Our combined expertise offers the potential to simplify joint reconstruction procedures, reduce variability and enhance the surgeon and patient experience. We look forward to welcoming the MAKO team to Stryker."

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter